VMS Asset Management
VMS Asset Management is a leading alternative asset management firm in the region, specializing in private equity, and structured finance.
Business Model: Consulting
Revenue: $8M
Employees: 11-50
Rankings
Industries / Tags:
Detailed VMS Asset Management Information
Geographic Data
Address: 8 Connaught Place
City: Central Hong Kong
State: other
Zip:
Country: HK
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Linkedin
Crunchbase
Metrics
3,858,021Website Global Rank
3,250Website Monthly Traffic
Twitter Followers
Description
VMS Group was established in 2006. Since then, it has grown to become a leading multi-strategy financial group providing specialized investment solutions and consulting services. Licensed with the Hong Kong Securities and Futures Commission to carry on business in Type 4 (Advising on Securities) and Type 9 (Asset Management) Regulated Activity, VMS Asset Management is the asset management arm of the Group, specializing in Private Equity investments. Its investment focus is on growth-stage companies in sectors across Healthcare, TMT (including new retail and new services) and Deep Tech. Leveraging on a Greater China focus with global connectivity value proposition, VMS has successfully completed more than 150 investments both onshore in China and offshore around the world since inception. Headquartered in Hong Kong with more than 70 staff and a presence in Beijing, VMS Group currently has in excess of USD 4.0 billion of assets under management.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 4/2018 | Youdao | Series A | - |
| 8/2017 | Keyssa | Series C | 15M |
| 4/2022 | Laiye | Series C | 0 |
| 6/2017 | Gamida Cell | Series F | 0 |
| 7/2019 | Dingdong Maicai | Series B | - |
| 6/2021 | CiDi | Series B | - |
| 12/2015 | Pharmaron | Venture Round | 280M |
| 8/2018 | Chemclin | Private Equity Round | 0 |
| 6/2015 | KingMed Diagnostics | Private Equity Round | - |
| 4/2015 | UCloud Information Technology | Series C | 100M |
| 5/2018 | Eden Biologics | Post-IPO Equity | 0 |
| 6/2019 | Bangsun Technology | Series C | 50.7M |
| 4/2015 | FinVolution Group | Series C | 46.7M |
| 4/2021 | BlissBio | Series B | - |
| 1/2019 | Zhangmen | Series E | 0 |
| 9/2021 | HAI ROBOTICS | Series C | 0 |
| 2/2021 | Didi Freight | Series A | 0 |
| 8/2018 | Profusa | Series C | 0 |
| 1/2018 | Meicai | Series E | 450M |
| 1/2018 | Pony.ai | Series A | 0 |
| 7/2018 | TalkingData | Venture Round | - |
| 11/2018 | Crossbar | Venture Round | 15.4M |
| 12/2021 | SyMap Medical | Series E | 100M |
| 7/2018 | Renrui Human Resources Technology Holdings | Series D | 14.5M |
| 7/2019 | I-Mab Biopharma | Series C | 27M |
| 5/2022 | CiDi | Series C | 0 |
| 5/2017 | Souche | Series D | 0 |
| 12/2021 | Uniskin | Series B | 0 |
| 2/2017 | iQiyi | Series G | 1.5B |
| 5/2019 | New Horizon Health | Series C | 0 |
| 12/2019 | Windtree Therapeutics | Post-IPO Equity | 26.4M |
| 3/2021 | Chime Biologics | Series A | 0 |
| 6/2021 | Inmagene Biopharmaceuticals | Series C | 0 |
| 4/2015 | Mediheal | Private Equity Round | - |
| 5/2022 | CiDi | Series C | 0 |
| 4/2022 | Laiye | Series C | 0 |
| 12/2021 | Uniskin | Series B | 0 |
| 12/2021 | SyMap Medical | Series E | 0 |
| 9/2021 | HAI ROBOTICS | Series C | 0 |
| 6/2021 | CiDi | Series B | - |
| 6/2021 | Inmagene Biopharmaceuticals | Series C | 0 |
| 4/2021 | Bliss Biopharmaceutical (Hangzhou) Co., Ltd. | Series B | - |
| 3/2021 | Chime Biologics | Series A | 0 |
| 2/2021 | Didi Freight | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
